We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Michael Susin AstraZeneca said that its drug Enhertu, which it developed in partnership with Daiichi Sankyo, has been approved in the European Union for the treatment of advanced non-small cell...
By Ben Glickman Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22 billion. Merck and Daiichi Sankyo will develop and...
By Christian Moess Laursen AstraZeneca said trial results for its breast cancer drug Dato-DXd showed significant improvement for the primary end-point of so-called progression-free survival in...
By Christian Moess Laursen AstraZeneca said its lung-cancer drug Enhertu has been recommended for approval in the European Union following positive test results. The Anglo-Swedish pharma giant...
By Anthony O. Goriainoff AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan, a cancer drug, combined with the Imfinzi cancer treatment--with or without chemotherapy--showed disease...
By Anthony O. Goriainoff AstraZeneca said Monday that its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions